DR. BARRY E. ROSENBLOOM, M.D.

Plain English
This research reviewed several studies to see if there is a link between childhood maltreatment and chronic pain later in life. Out of the nine studies analyzed, which included over 17,000 participants, evidence was inconsistent and mostly of low quality, with only some high-quality studies showing no strong connections between maltreatment and pain. The findings highlight that post-traumatic stress disorder (PTSD) might play a role, but overall, there’s not enough solid evidence to confirm that childhood maltreatment directly leads to chronic pain. Who this helps: This helps researchers and medical professionals understand the complexities of how childhood experiences may affect long-term health.

Plain English
This study looked at how certain genetic factors affect the risk of severe COVID-19. Researchers found that a specific genetic variation in Europeans, linked to a piece of DNA inherited from Neandertals, increases the risk of being hospitalized for COVID-19, particularly due to difficulties in clearing the virus without treatment. They identified two specific genetic variations that can disrupt normal virus-fighting processes, suggesting that some people might need different treatments, like interferons, to help their bodies fight off the virus. Who this helps: This research can benefit patients at higher risk for severe COVID-19, especially those with the identified genetic variations.

Plain English
This study looked at two men with Gaucher disease who were diagnosed with a type of cancer called diffuse large B-cell non-Hodgkin's lymphoma (DLBCL). One man, diagnosed at age 66, faced multiple treatments but eventually died from complications related to his cancer and treatment; the other man, diagnosed at age 22, is currently in remission after switching his therapy regimen. These findings are important because they highlight the increased risk of certain cancers, like DLBCL, in people with Gaucher disease, which can help improve monitoring and treatment strategies. Who this helps: This helps patients with Gaucher disease and their doctors by informing them about potential cancer risks.

Plain English
This study looked at how children's anxiety levels before and after surgery affect their memories of pain one year later. Researchers followed 237 children and found that those who experienced higher anxiety soon after surgery recalled greater pain than they originally reported, with a clear link between their anxiety at the start of the study and their pain memories a year later. This is important because it suggests that helping children manage anxiety around surgery could lead to more accurate pain memories and potentially reduce the development of chronic pain. Who this helps: This benefits children undergoing surgery and the doctors who care for them.

Plain English
Researchers studied the long-term effects of a medication called eliglustat on patients with Gaucher disease type 1 who were already being treated with enzyme therapy. They found that after 4 years, more than 85% of the patients maintained stable health markers such as platelet counts and liver volume, and only 2.5% stopped treatment due to side effects. This is important because it shows that eliglustat is an effective long-term treatment option for these patients, helping them stay stable without worsening symptoms. Who this helps: Patients with Gaucher disease type 1.

Plain English
This study looked at how the severe symptoms of Gaucher disease type 1 (GD1) patients have changed over 20 years after starting enzyme replacement therapy (ERT) with alglucerase/imiglucerase. It found that the need for spleen removal (splenectomy) has dropped significantly, and the severity of bone problems in patients starting treatment has also decreased, particularly in children. This matters because it indicates that earlier treatment and improved care standards are helping to prevent serious complications associated with GD1. Who this helps: This helps patients with Gaucher disease and their doctors.

Plain English
This study looked at how information about critically injured trauma patients can get lost when they are transferred from the emergency department to the intensive care unit. Researchers found that in 48% of cases, important clinical information was missing, and 24% of patients had injuries that were overlooked. This is significant because patients with missing information were more likely to have unknown medical histories and may experience changes in their treatment plans. Who this helps: This benefits patients by improving the accuracy of their care during critical transfers.

Plain English
This study looked at whether patients with Gaucher's disease type 1, who are stable on enzyme replacement therapy (ERT), could switch safely to an oral medication called eliglustat. After 12 months, 85% of patients on eliglustat and 94% on imiglucerase (the traditional infusion treatment) maintained stable blood and organ measurements, showing that eliglustat is as effective as imiglucerase. These findings are important because they suggest that patients can switch to an easier oral treatment without losing control over their disease. Who this helps: This helps patients with Gaucher's disease by providing an alternative treatment option that could be more convenient and easier to manage.

Plain English
This study looked at the safety of a new treatment called velaglucerase alfa for patients with type 1 Gaucher disease, especially during a time when another treatment was in short supply. Out of 211 patients, 17.1% of those who had previously received a different treatment experienced some side effects linked to velaglucerase alfa, while only one out of six new patients did. The findings show that velaglucerase alfa is safe and a good alternative for patients starting treatment or switching from the other drug. Who this helps: This benefits patients with Gaucher disease and their doctors by providing a reliable treatment option.

Plain English
This study reviewed the use of electronic headache diaries (e-diaries) to track headache pain in both children and adults. Researchers examined 21 publications and found that while five e-diaries were well-defined enough for analysis, none had strong evidence proving they reliably measure headache pain. The study highlights that e-diaries often lack the necessary validation, and many don’t even track headache frequency as recommended, indicating that improvements are needed in their design and testing to better serve patients. Who this helps: This benefits patients who suffer from headaches and need effective ways to track and manage their symptoms.

Plain English
This study looked at patients with type 1 Gaucher disease who continued to have low platelet counts (thrombocytopenia) even after receiving enzyme treatment (imiglucerase) for 4 to 5 years. Out of 1,016 patients, those with a platelet count below 80 x 10^9/L at the start of treatment, as well as those with enlarged spleens and anemia, were more likely to have ongoing low platelet counts. Specifically, low platelet counts were strongly associated with serious conditions like enlarged spleen and anemia, which could complicate treatment. Who this helps: Patients with type 1 Gaucher disease who struggle with low platelet counts.

Plain English
This study looked at how common Parkinsonism is among patients with type 1 Gaucher disease, comparing those who have it to those who don't. They found that 10-12% of Gaucher patients develop Parkinsonism before age 80, which is significantly higher than seen in the general population. Interestingly, patients with Parkinsonism had a later diagnosis of Gaucher disease and did not show more severe symptoms compared to those without Parkinsonism. Who this helps: This information benefits Gaucher disease patients and their doctors by improving understanding of potential Parkinsonism risks.

Plain English
This study looked at a treatment called alglucosidase alfa for people with late-onset Pompe's disease, a condition that causes severe muscle weakness and breathing problems. Researchers gave 90 patients either alglucosidase alfa or a placebo for 78 weeks and found that those on the treatment walked an average of about 28 meters farther in six minutes and had a slight improvement in lung function compared to those who didn't receive it. This matters because it shows that alglucosidase alfa can help improve mobility and stabilize breathing in patients with this serious disease. Who this helps: This helps patients with late-onset Pompe's disease and their doctors.

Plain English
This study looked at how imiglucerase, a treatment for type 1 Gaucher disease, improves the quality of life for patients experiencing bone-related issues like pain and fractures. Involving 32 patients, the research found that after two years of treatment, their scores on health assessments improved significantly, bringing them back to normal levels. Even those with severe bone problems saw major improvements, showing that imiglucerase can help these patients feel better physically and mentally. Who this helps: Patients with type 1 Gaucher disease who have skeletal complications.

Plain English
This study tested a treatment called elsamitrucin for patients with relapsed or stubborn non-Hodgkin's lymphoma, a type of blood cancer. Out of 31 patients, 13% saw their tumors reduce in size, while another 30% had their disease stabilize without significant side effects like severe blood count drops. This research is important because it shows that elsamitrucin may be a safe and effective option for these patients when combined with other treatments. Who this helps: Patients with relapsed or refractory non-Hodgkin's lymphoma.

Plain English
This study looked at a condition called therapy-related myelodysplastic syndromes, which can occur in patients who have received certain cancer treatments, like chemotherapy or radiation. It found that these treatments can lead to changes in blood cells, making it harder for the body to produce healthy blood. Understanding this condition is crucial because it helps doctors manage and treat patients who have received these therapies more effectively. Who this helps: This benefits patients who have undergone cancer treatment.

Plain English
This study looked at a rare blood disorder called T-gamma-lymphoproliferative disorder in a 42-year-old woman who had several autoimmune diseases. Researchers found that her blood showed abnormal T-cells and she experienced many infections, eventually developing serious conditions like plasma cell dyscrasia and amyloidosis before she passed away. This matters because it highlights the complicated relationship between autoimmune diseases and severe blood disorders, helping doctors better understand these connections. Who this helps: This helps patients with autoimmune diseases and their doctors.

Plain English
Researchers studied four patients with moderately severe type I Gaucher disease to see how well a specific enzyme replacement therapy called Ceredase could help them. After up to 13 months of treatment, they found significant improvements in liver size and function, blood counts, and certain enzyme levels, while those with lung issues showed better lung function. However, there was no change in bone health. Who this helps: This helps patients with Gaucher disease and their doctors.

Plain English
In this study, researchers examined a rare and severe reaction called hyperpyrexia—extremely high fever—after administering bleomycin, a drug commonly used to treat cancer. They reported a case where a patient experienced this fatal reaction after having received the drug without issues in the past, highlighting that such risks can occur even after prior successful treatments. Understanding this risk is crucial for better patient management and safety during cancer therapy. Who this helps: This helps doctors and oncologists make safer treatment decisions for their patients.

Plain English
This study looked at treating 134 patients with advanced cancer using high doses of a drug called methotrexate, followed by a rescue medication to reduce side effects. Out of the patients treated, 29% showed some level of improvement, with 33 experiencing partial recovery and 6 patients fully recovering. The treatment was generally safe and didn't cause significant or unexpected side effects, suggesting it could be a promising option for patients who haven't responded to other treatments. Who this helps: This helps cancer patients, especially those with advanced diseases who haven't had success with previous therapies.

Plain English
This study looks at two similar illnesses caused by viruses: infectious mononucleosis (IM) from Epstein-Barr virus (EBV) and mononucleosis from cytomegalovirus (CMV). It found that people with IM typically produce a specific antibody that those with CMV do not, and that IM often affects certain immune cells in a particular order, unlike CMV. Understanding these differences is important for better diagnosis and treatment, as complications can vary widely; for instance, CMV infections can be more severe in babies who get the virus before or during birth, while IM complications are usually self-limiting except in some males with a genetic issue. Who this helps: This helps doctors and patients by improving understanding of these viral infections and their potential complications.

Plain English
This study looked at how to safely perform oral surgeries on patients who take blood thinners (anticoagulants), which can increase the risk of blood clots. The researchers developed a method that allows these patients to have surgery while minimizing the time they stop taking their anticoagulant medication, thus reducing their risk of complications. This approach is important because it helps manage the delicate balance of preventing bleeding during surgery while also protecting patients from blood clots. Who this helps: This benefits patients who need oral surgery but are at risk of blood clots due to anticoagulant use.